Short answer
Alnylam Pharmaceuticals (ALNY) filed an 8-K current report with the SEC on March 4, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). CEO Dr. Greenstreet granted 55,373 target PSUs on March 2, 2026 with face value of $18.0M at $325.07/share.
Alnylam Pharmaceuticals 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CEO Dr. Greenstreet granted 55,373 target PSUs on March 2, 2026 with face value of $18.0M at $325.07/share
- 100% performance-based; minimum threshold $500/share (~54% above grant date price) must be met or award forfeits entirely
- Payout range: 50% of target at $500/share up to 200% of target (110,746 shares) at $800/share; all by Dec 31, 2029
- Baseline threshold exceeds ALNY all-time high as of grant date: a meaningful retention/alignment tool tied to substantial new value creation
- Board explicitly frames award as retention anchor for "Alnylam 2030" five-year plan, following ~100% stockholder return under Greenstreet's prior tenure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Alnylam Pharmaceuticals 8-K filings
Get the next ALNY 8-K as it lands
Follow ALNY for push alerts, or ask the research agent what this filing means.